

Simlandi[®] (adalimumab-ryvk) – New biosimilar launch

- On May 20, 2024, [Alvotech](#) and [Teva](#) launched [Simlandi \(adalimumab-ryvk\)](#), an *interchangeable* biosimilar to AbbVie's [Humira[®] \(adalimumab\)](#).
 - Simlandi is available as a 40 mg/0.4 mL single-dose autoinjector.
- The [FDA approved](#) Simlandi in February 2024 for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, ulcerative colitis (UC), plaque psoriasis, hidradenitis suppurativa (HS) and uveitis.
- Humira is also approved for the treatment for UC in pediatric patients 5 years and older, HS in 12 years of age and older, and uveitis in 2 years of age and older.